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Introduction
It is not unusual for certain insulinomas and gastrino-
mas to escape preoperative detection as well as intraop-
erative identification because of their small size and/or
particular localization. According to Cirillo et al.1 and
Ressetta et al.2, this occurs in 10-30% of cases, while
Adams and Baum3 reported such a situation in 20% of
insulinomas and 40% of gastrinomas. This circum-
stance may even persist in the presence of evident
metastases, particularly in cases of gastrinoma. From
the surgeon’s point of view, this is the most baffling as-
pect of neuroendocrine tumors, although nuclear medi-
cine technologies are now capable of providing valu-
able, often critically important assistance. It is in this
context that the synthetic analogs of somatostatin (SST)
labeled with radioactive isotopes come into play, since
they make it possible to preoperatively image occult le-
sions with scintigraphy and to localize them intraopera-
tively using a hand-held gamma probe. With respect to
scintigraphy, the intraoperative probe has the advantage
of depicting the lesion with great precision in terms of
both size and topographic location, although the slow
clearance of the tracer from surrounding tissues in addi-
tion to its accumulation in the liver, the kidney and the
spleen must be taken into account.
Patients and methods
Our study involved 3 patients with different types of
malignant gastroenteropancreatic (GEP) apudoma. 
Case 1 
The first patient was a 64-year-old woman who, at
the age of 39, had undergone enucleation resection of
an insulinoma of the pancreatic body, the histological
nature of which was uncertain. Seventeen years later,
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Aims and background: In neuroendocrine tumors of the gastroen-
teropancreatic (GEP) system, radiolabeled analogs of somato-
statin (SST) are useful to the surgeon in different phases of
treatment: preoperatively, to identify the lesion with somato-
statin receptor scintigraphy (SRS), intraoperatively for localiza-
tion using a hand-held gamma probe, and postoperatively act-
ing directly to eliminate any residual tumor cells. Additional
features of these analogs that are of value in treating such
GEP tumors include their antiproliferative potential, which is in
the process of being verified, and, above all, their anti-secreto-
ry action, so effective in symptom control. In this study the au-
thors, based on their own experience, evaluate the effective-
ness of SST analogs in treating GEP endocrine tumors.
Methods: Three patients with malignant GEP apudomas were
studied. In case 1, an insulinoma, the patient underwent four
surgical procedures for ablation of the pancreatic tumor and of
hepatic and lymph node metastases in addition to local ra-
diofrequency treatment and radiometabolic therapy. Case 2
was a carcinoid tumor of the small intestine with hepatic
metastases, managed by ileal resection, local radiofrequency
treatment and receptor-mediated radionuclide therapy. In case
3, a non-functioning pancreatic carcinoma with liver and lymph
node metastases, the patient underwent four surgical proce-
dures, hepatic chemoembolization, antiproliferative treatment
using octreotide (OCT) and metabolic radionuclide therapy.
Results: In all three cases SRS proved highly sensitive in the
early detection of even the smallest recurrences. There was
uncertainty, however, regarding the effectiveness of therapy
with radiolabeled SST analogs. Hepatic metastases from the
carcinoid were completely unresponsive, but in the case of
the insulinoma, the hepatic metastases showed necrosis fol-
lowing treatment, while lymph node metastases were unaf-
fected. In the case of the non-functioning carcinoma, there
was a correlation between treatment and a marked improve-
ment in the patient’s clinical condition, although the appear-
ance of the lesions themselves remained unchanged. The an-
tiproliferative effect of OCT in this case was nil.
Conclusions: SRS proved highly accurate in detecting recur-
rences during follow-up. The merits of radiometabolic therapy,
on the other hand, were unclear, a finding reported elsewhere
in the literature, and in the only case treated by prolonged
OCT treatment, no antiproliferative action was observed. The
diagnostic usefulness of SRS was thus confirmed and it ap-
pears likely that radiolabeled analogs used intraoperatively
for tumor localization will prove equally of value. The effec-
tiveness of receptor-mediated radionuclide therapy is still in
the process of being verified. Based on the expectation of
analogs with an universal affinity for SST receptors (sst), it is
reasonable to look forward to a significant increase in the effi-
cacy of this type of therapy.
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the patient presented with a frankly carcinomatous re-
currence associated with sporadic episodes of hypo-
glycemia. Left pancreatectomy and splenectomy were
performed, resulting in definitive remission of the hy-
poglycemic syndrome. After an interval of 22 years
from the original procedure, 2 large paraaortic metas-
tases at the level of the renal vessels (Figure 1) and two
hepatic metastases located in segment VI of the liver
were treated in a single surgical session by resection
and radiofrequency therapy, respectively. Three months
later, a follow-up CT exam showed the presence, con-
firmed by somatostatin receptor scintigraphy (SRS)
with 111In-pentetreotide, of another enlarged paraaortic
lymph node. In the years that followed the first reoper-
ation, the patient’s plasma concentrations of chromo-
granin A (CgA) (173.1-274.2 ng/mL, normal value
<123 ng/mL) and pancreatic polypeptide (PP) (77.7-
268 pg/mL, normal value <85.8 pg/mL) rose by vary-
ing increments. The scintigraphic exam carried out dur-
ing the first cycle of radiometabolic therapy with 90Y-
DOTA0-Tyr3-octreotide (90Y-DOTATOC) showed, in
addition to the paraaortic uptake, a suspicious area of
concentration in segment VI of the liver, which was
subsequently confirmed by US and MRI. After 4 cycles
of therapy (total MBq: 4,932) with intervals of 6 weeks
between treatments, the size of the lesions appeared
unchanged at CT and the levels of plasma CgA and PP
remained elevated (425 ng/mL and 476 pg/mL, respec-
tively), while SRS was inconclusive. A fourth surgical
procedure was then performed, this time consisting of a
wedge resection of segment VI of the liver to remove
the mass confirmed at intraoperative US and the resec-
tion of two lymph nodes in the vicinity of those previ-
ously removed.
The surgical specimen was fixed in buffered formalin
and the entire hepatic lesion was sampled for histologi-
cal evaluation. In addition, immunohistochemical stain-
ing for endocrine markers was performed. On histologi-
cal examination the lesion was mainly constituted by an
eosinophilic non-homogeneous necrotic area surround-
ed by a collagen rim (Figure 2). Rare clusters of en-
docrine neoplastic cells were found in the context of the
necrotic hepatic area. Moreover, neoplastic cells were
found in two resected lymph nodes. No neoplastic cells
were observed in the hepatic resection margins. The en-
docrine phenotype of the residual neoplastic cells was
confirmed by immunohistochemistry (insulin, synapto-
physin). 
During the postoperative course, the patient’s plasma
CgA was found to be unusually elevated (>700 ng/mL),
a finding related to treatment with omeprazole. When
use of the drug was discontinued, the CgA level re-
turned to normal (82.1 ng/mL). 
Case 2
The second patient was a 62-year-old male who, at
the age of 48, had undergone a left hemicolectomy for
Figure 1 - Two paraaortic lymph node metastases (arrows) on CT/scinti-
graphic scans and at surgery.
Figure 2 - Large necrotic area surrounded by a collagenous rim. The he-
patic tissue outside the lesion is normal.
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carcinoma of the colon. Ten years later, during follow-
up, the patient, who was asymptomatic, was found at
US, CT and MRI to have multiple hepatic lesions which
were thought to be of an angiomatous nature. Three
years later, because of the increase in the number and
size of these lesions, a new MRI using the superpara-
magnetic contrast agent Endorem® was carried out, the
result of which was suggestive of metastasis. This was
confirmed by cytological analysis of the needle-aspira-
tion biopsy, which resulted in a diagnosis of “neuroen-
docrine neoplasia”. The definitive diagnosis of ileal car-
cinoid tumor with metastasis to the liver was based on
elevated plasma levels of serotonin (5-HT) (538 ng/mL,
normal 90-180 ng/mL) and PP (121.7 pg/mL, normal
<85.8 pg/mL) and an increase in urinary 5-hydroxyin-
dole acetic acid (5-HIAA) (17.5 mg/24h, normal 2-6
mg/24h). SRS showed multiple areas of uptake in the
liver and in the right mesogastric zone. Surgical treat-
ment consisted of resection of a 105 cm length of ileum
in which there were 7 small tumor foci located 10-
15 cm apart (Figure 3). A superficial liver metastasis
was also excised, while 6 additional liver lesions were
treated by US-guided radiofrequency ablation. Treat-
ment of an ulterior liver lesion adjacent to the vena cava
was deemed unfeasible. Sixteen of the 17 lymph nodes
removed at the origin of the upper mesenteric artery
showed tumor infiltration. Four cycles of radiometabol-
ic therapy using 90Y-DOTATOC at 6-week intervals for
a total of 5,720 MBq produced no appreciable effect on
the residual metastasis, as confirmed by CT and scintig-
raphy. While the levels of plasma 5-HT (270 ng/mL)
and urinary 5-HIAA (12.1 mg/24h) remain elevated, the
patient is currently in satisfactory condition, with no
symptoms.
Case 3
The third patient was a 57-year-old man who, at the
age of 47, had undergone a cephalic duodenopancreatec-
tomy for a non-functioning neuroendocrine tumor of the
head of the pancreas and excision of three metastatic le-
sions located in liver segments V, VI and VII. Recur-
rence of the disease after four years required a wedge re-
section for a metastasis in segment VIII of the liver.
Three courses of hepatic chemoembolization were car-
ried out at brief intervals, the latest 4 years ago, using
streptozotocin and lipiodol plus gelatin sponge (Spon-
gel) as the embolizing agent. Subsequently, octreotide
(OCT) therapy was administered in two different formu-
lations, first with immediate release (IR) (0.5 mg daily
for two years) and then with long-acting release (LAR)
(30 mg every four weeks for 18 months until metabolic
radionuclide therapy was initiated). The effects of both
OCT therapy and chemoembolization, however, proved
negligible. In October 2003, 9 years after the first surgi-
cal procedure, the patient was operated on again, this
time for excision of a large collection of lymph nodes at
the origin of the upper mesenteric artery. In January
2004, US and CT monitoring showed hepatic recurrence
(three lesions <1 cm) confirmed by SRS, as well as new
lymph node metastases at the site mentioned above (Fig-
ure 4). Radionuclide therapy (4 cycles of 90Y-DOTATOC
administered at six-week intervals for a total of 6,138
MBq) coincided with clinical improvement, specifically
a weight gain of 10 kg and the disappearance of epigas-
tric and lumbar pain which, until then, had been experi-
enced by the patient almost daily. No such improvement,
Figure 3 - Multiple ileal localizations of a carcinoid tumor with metasta-
sis to the liver; at the lower left, MR image of a liver metastasis (arrow);
at the upper right, scintigraphic scan showing areas of uptake in the liver
and the right mesogastric zone. 
Figure 4 - CT image of a large collection of lymph nodes at the origin of
the superior mesenteric artery and the corresponding area of intense up-
take at octreotide scintigraphy; CT also clearly depicts multiple hypo-
dense foci in the liver as well as hypertrophy of residual liver segments
resulting from prior metastasectomy.
however, was observed on CT and scintigraphic images,
nor was there any decrease in plasma CgA (320 ng/mL,
normal ≤123 ng/mL).
Results
The wide range of diagnostic and therapeutic possi-
bilities anticipated for the synthetic analogs of somato-
statin with regard to GEP endocrine tumors was only
partially verified in the present study. Among the feasi-
ble goals of these analogs in clinical practice, only
those concerning preoperative diagnosis and postopera-
tive therapy (particularly antiproliferative and metabolic
radionuclide therapy) were tested. The fact that none of
the three patients studied had clinical manifestations
linked to an endocrine function of the tumor in question
rendered any assessment of the effect on symptoms
meaningless. In previous clinical observations we had
seen that OCT is rarely effective against a hypo-
glycemic syndrome caused by insulinoma (only 2 re-
missions out of 13 cases treated). In the only case of
glucagonoma studied, the action of OCT was rapid and
total, whereas the biochemical effect was extremely
limited4,5. 
In all three cases described in this study, the diagnos-
tic sensitivity of SST analogs using a radioactive mark-
er for the early detection of even very small tumor re-
currences in the course of long-term follow-up was con-
firmed. Use of SRS, in fact, repeated periodically in
each case, demonstrated high overall accuracy. The
negative result obtained in the case of liver metastases
from an insulinoma is very likely attributable to the
necrosis of much of the metastatic tissue, as evidenced
by histological examination (Figure 2). We had no occa-
sion to verify the effectiveness of this modality in what
would be the logical sequence to its use for diagnosis,
i.e., for the intraoperative radioguided localization of
tumor lesions.
As far as receptor-mediated radionuclide therapy is
concerned, there is much uncertainty regarding its ef-
fectiveness. Liver metastases from the carcinoid tumor
showed no response to treatment, while the liver metas-
tasis from the insulinoma underwent near total necrosis,
although lymph node metastases in the same case were
unaffected. In the case of the non-functioning carcino-
ma, the patient’s clinical condition showed marked im-
provement after just two treatment cycles, a circum-
stance, however, clearly inconsistent with the informa-
tion provided by imaging studies. At any rate, we feel
that it is worthwhile to persevere in researching this
modality. It would be an error to ignore the potential of
a vehicle capable of delivering a quantity of radioactivi-
ty to the interior of tumor cells a hundred times that
transmitted to normal tissue.
An attempt to use OCT for its antiproliferative ac-
tion was made only in the case involving the non-
functioning metastasized tumor. Treatment was contin-
ued for a period of three and a half years with no ob-
servable effect. 
Discussion and conclusions
Clinically, ample use has been made of the well-
known inhibitory action of SST and its synthetic
analogs on endocrine and exocrine hyperfunction asso-
ciated with inflammation, hyperplasia and neuroen-
docrine tumors of the gastrointestinal tract. This effect
is based on the interaction with SST receptors (sst)1-5
in the membrane of target cells. Natural SST has an
affinity for all 5 receptor subtypes, while OCT, the ana-
log most commonly used, has a strong affinity for sst2
and a much lower affinity for sst subtypes 3 and 5. In-
sulinomas, unlike other GEP endocrine tumors, are
poorly endowed with these receptors, and consequently
symptoms in this type of lesion are typically unaffected
by OCT treatment. They may even worsen due to the
analog’s concomitant inhibitory effect on the release of
glucagon and GH.
The interaction of SST or its analogs with specific re-
ceptors is utilized not only to control symptoms but also
diagnostically (SRS) and therapeutically (radiometabol-
ic therapy): octapeptide analogs radiolabeled with 111In-
dium, 90Yttrium and 177Lutetium reach the surface of the
tumor cells where they are taken up and internalized by
means of endocytosis in the lysosomes of the cytoplasm
and subsequently in the DNA of the nucleus. Thanks to
this feature, such tumors become sources of radioactivi-
ty which can be externally detected with the proper
imaging technique. At the same time, the energy pro-
duced by the electromagnetic radiation gives rise to ion-
ization phenomena in the tumor tissue itself. If the half-
life of the radioisotope is of adequate duration, as in the
case of 111In-pentreotide, a single dose should suffice to
carry out preoperative scintigraphy, radioguided intra-
operative localization, and postoperative scintigraphy.
Of course, this capability depends on an appropriate
protocol, with imaging carried out no earlier than 24-48
hours from the administration of the marker, so that it
can be cleared from the circulation, from the parenchy-
mous organs and from the intestine. 
Our experience enabled us to confirm the diagnostic
usefulness of octreotide. Therapeutically, however, it
proved to be of scant and fluctuating effectiveness,
characteristics which would appear to be linked to the
limited affinity of OCT for SST receptors. Newly avail-
able analogs capable of interacting with all or most of
these receptor subtypes give promise of a heightened
therapeutic potential, much like that of radioiodine in
differentiated thyroid carcinomas. This prospective is
already an experimental reality with regard to the ana-
log SOM230, the universal ligand of all sst subtypes ex-
cept sst46,7.
For the moment, however, the therapeutic efficacy of
OCT remains basically unreliable. Paganelli et al.8, Cuc-
curullo et al.9, and Lombardi and Pivonello10 all report the
remission of symptoms in approximately 15% of cases, a
reduction in the tumor mass in 25%, stabilization in 35-
55%, a >50% decrease in incretion in 81%, and a total
lack of response in 20%. Ricci et al.11, on the other hand,
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reports a single objectively positive response (naturally
partial) out of 15 patients treated and a biochemical/symp-
tomatic response in roughly half of the patients.
The outcome of therapy in the three cases reported is
equivocal: ineffectual in treating hepatic metastases
from the carcinoid, positive for hepatic metastases from
the insulinoma, and apparently of considerable benefit
in terms of the patient’s general condition in the metas-
tasized non-functioning carcinoma of the pancreas, de-
spite the absence of any evident modification of the le-
sions at scintigraphy and CT. 
In addition to inhibiting the production and release of
substances that interact as hormones, SST and its
analogs seem to have a direct antiproliferative effect on
tumors, limiting their increase in volume and, in some
cases, even reducing it12,13. To obtain such results, it is
necessary to maintain high plasma levels of the drugs, a
condition made possible by the use of slow-release
preparations to be administered once every two to four
weeks. In our case (no. 3), however, this effect was not
observed.
Overall, our limited experience confirms that an in-
terdisciplinary approach in the treatment of GEP en-
docrine tumors, involving the use of debulking surgery,
radiofrequency therapy, chemotherapy, chemoemboliza-
tion, radiometabolic therapy, interferon and SST
analogs, results in a more favorable outcome. We also
came to the conclusion that in this particular category of
tumors, even when dealing with malignant, metasta-
sized and diffuse lesions13-15, one must not yield to an
attitude of resignation. Reasonably aggressive treatment
often produces results thought to be unobtainable.
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